Why the study?
DOX-based chemotherapy causes severe systemic side effects, prompting the exploration of strategies such as nanocarriers, conjugates, structural modifications, immunotherapy, and combination therapy to improve efficacy and safety.
Advanced formulations of doxorubicin, including nanocarriers and conjugates, require clinical trials to improve efficacy and safety in cancer chemotherapy.
Answers are grounded in this paper and cite their sources.
Clinicians should await dedicated trials before using advanced doxorubicin formulations; leaves open their net benefit in cancer therapy.
DOX-based chemotherapy is still few steps away from being "perfect and safe" therapy. Certain severe systemic side effects are associated with DOX therapy. It is expected that, in the near future, DOX therapy can be much effective by selecting an ideal nanocarrier system, DOX conjugates, proper structural modifications, DOX-immunotherapy, and combination therapy. The advanced formulationsof DOX from the registered patents and recent research articles need clinical trials to bring safe treatment for cancer patients.
No takes yet. Share an insight, caveat, or question.
Sohail et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: